Kornitzer Capital Management Upped By $6.19 Million Its Akorn (AKRX) Position; 2 Bullish Analysts Covering Adaptimmune Therapeutics PLC – ADR (ADAP)

August 25, 2017 - By Vivian Currie

Among 4 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Adaptimmune Therapeutics PLC had 4 analyst reports since February 25, 2016 according to SRatingsIntel. The company was downgraded on Monday, October 24 by Bank of America. On Thursday, February 25 the stock rating was initiated by Citigroup with “Buy”. Cowen & Co maintained the shares of ADAP in report on Tuesday, June 6 with “Buy” rating. See Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) latest ratings:

06/06/2017 Broker: Cowen & Co Rating: Buy Maintain
17/03/2017 Broker: Wells Fargo Rating: Market Perform Initiates Coverage On

Kornitzer Capital Management Inc increased Akorn Inc (AKRX) stake by 32.01% reported in 2016Q4 SEC filing. Kornitzer Capital Management Inc acquired 294,855 shares as Akorn Inc (AKRX)’s stock rose 52.48%. The Kornitzer Capital Management Inc holds 1.22 million shares with $26.55M value, up from 921,208 last quarter. Akorn Inc now has $4.04 billion valuation. The stock increased 0.12% or $0.04 during the last trading session, reaching $32.36. About shares traded. Akorn, Inc. (NASDAQ:AKRX) has risen 12.04% since August 25, 2016 and is uptrending. It has underperformed by 4.66% the S&P500.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The company has market cap of $490.98 million. The Firm is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor T-cell platform. It currently has negative earnings. The Firm has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

The stock increased 0.19% or $0.01 during the last trading session, reaching $5.25. About shares traded. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has declined 43.56% since August 25, 2016 and is downtrending. It has underperformed by 60.26% the S&P500.